Effectiveness of a Structured Pharmacist-led Intervention in Improving Pediatric Outpatient Prescribing Quality in a Resource-limited Setting: A Pre–post Study Authors: Thang Nguyen, Lam Tran Hong Huynh, Anh Ngoc Phuong Nguyen, Phuong Minh Nguyen, Duy Khanh Dang Published: 2026 ABSTRACT Objective:The objective is to determine the prevalence and types of drug-related problems (DRPs), identify associated factors, and evaluate the impact of a structured pharmacist-led intervention on prescribing quality in pediatric outpatient care in a resource-limited health system with limited advanced prescribing decision-support.Methods:A pre–post intervention study was conducted from July 2023 to June 2024 at a secondary-level hospital in a lower-middle-income country setting (Vietnam). Two independent cross-sectional prescription samples were obtained using systematic random sampling (323 prescriptions preintervention and 323 postintervention). DRPs were identified using national prescribing frameworks and mapped to the Pharmaceutical Care Network Europe DRP Classification (v9.1). The intervention comprised pharmacist-led educational sessions and the dissemination of drug information bulletins, with ongoing reminders, targeting the most frequent baseline DRPs. Factors associated with DRP occurrence (≥1 DRP per prescription) were examined using logistic regression; pre–post comparisons used Chi-square tests.Findings:At baseline, 57.9% of prescriptions contained at least one DRP, predominantly dosage regimen-related problems, with incorrect timing of administration being the most frequent (32.20%). In multivariable analysis, prescriptions issued by male prescribers had higher odds of DRPs (odds ratio 2.51, 95% confidence interval 1.51–4.18), whereas prescriptions for children aged 2–6 years and 6–12 years had lower odds than those for children aged ≤2 years. Following the intervention, DRP prevalence decreased significantly to 40.2% (P < 0.001), with marked reductions in timing- and dosing-related DRPs.Conclusion:A structured, low-cost pharmacist-led intervention integrated into routine outpatient practice was associated with a clinically meaningful reduction in DRPs. Strengthening clinical pharmacy services is a feasible and scalable strategy to improve pediatric prescribing safety in resource-limited settings where systematic medication review and electronic decision support are constrained. INTRODUCTION Drug-related problems (DRPs) are a major and largely preventable threat to the safe and effective use of medicines, contributing to avoidable patient harm and inefficient healthcare utilization. In response to this global burden, the World Health Organization (WHO) launched the Global Patient Safety Challenge “Medication Without Harm,” emphasizing system-level strategies to reduce preventable medication-related injury.[1] Evidence syntheses have further demonstrated that medicine-related problems contribute substantially to hospitalizations, many of which may be preventable through improved prescribing practices and structured medication management.[23] Pediatric patients are particularly vulnerable to DRPs because medication use must be individualized according to age-dependent physiology, wide weight variability, and developmental changes in pharmacokinetics and pharmacodynamics.[456] Medication errors – defined by the National Coordinating Council for Medication Error Reporting and Prevention as preventable events that may cause or lead to inappropriate medication use or patient harm – remain common in children.[7] Large safety studies and systematic reviews consistently show that preventable adverse drug events and prescribing errors are frequent in pediatric care, with dosing and administration errors among the most modifiable problems across the medication-use process.[4568] A recent systematic review focusing on pediatric DRPs concluded that these problems are common, largely preventable, and that clinical pharmacy services are among the interventions most consistently associated with reductions in DRPs.[9] In low-and middle-income country settings, pediatric outpatient prescribing is often further complicated by limited access to child-appropriate formulations, variable decision-support resources, and inconsistent integration of clinical pharmacy services into routine care.[910] In Vietnam, DRPs in pediatric outpatient settings remain under-recognized and relatively under-evaluated in intervention studies. A large outpatient study in Can Tho found that 65.7% of pediatric outpatient prescriptions contained at least one DRP, highlighting the scale of the problem in routine practice.[11] Vietnam has established regulatory and technical frameworks to support safer outpatient prescribing and DRP monitoring, including national outpatient prescribing regulations (Circular No. 18/2018/TT-BYT),[12] a Ministry of Health drug use review tool (Decision No. 3547/QĐ-BYT),[13] and a national list of contraindicated drug interactions (Decision No. 5948/QĐ-BYT).[14] To ensure reproducible and internationally comparable DRP assessment, this study applied the Pharmaceutical Care Network Europe (PCNE) Classification for DRPs (version 9.1).[1516] The DRP construct also underpins pharmaceutical care practice and structured medication management interventions.[17] Building on baseline evidence from Kien Giang Province indicating a high prevalence of DRPs in pediatric outpatient prescriptions, we evaluated a structured clinical pharmacy intervention integrated into routine outpatient prescribing at a regional pediatric referral hospital in southern Vietnam. Accordingly, this study aimed to (i) determine the prevalence of prescriptions containing at least one DRP among pediatric outpatients; (ii) describe the types of DRPs identified; (iii) examine prescribing factors associated with DRP occurrence; and (iv) evaluate the effectiveness of a structured clinical pharmacy intervention in reducing DRPs. METHODS A quasi-experimental before-and-after study using two independent cross-sectional prescription samples was conducted in the pediatric outpatient clinics of a secondary-level regional referral pediatric hospital in southern Vietnam. The study period spanned July 2023 to June 2024 and comprised three phases: a preintervention assessment, implementation of a structured clinical pharmacy intervention, and a postintervention assessment. The study population included (i) prescribing physicians and (ii) pediatric outpatient prescriptions. All physicians routinely prescribing in the pediatric outpatient clinics during the study period were eligible. Physicians who did not work continuously throughout the study period or declined to participate were excluded. The unit of analysis was the outpatient prescription. Prescriptions were eligible if they were issued for patients aged ≤16 years, covered by national health insurance, prescribed by eligible physicians, and documented in accordance with Circular No. 18/2018/TT-BYT.[12] Prescriptions were excluded if they were repeat prescriptions for the same patient with the same diagnosis and identical medication regimens within 1 month; contained only topical medicines or medicines used exclusively for minor procedures; or lacked essential prescribing information (diagnosis, medicine name, dose, frequency, or route of administration). The required sample size for each phase was calculated using the single-proportion method for cross-sectional studies, informed by previously reported DRP prevalence in Vietnamese pediatric outpatient settings and a predefined absolute precision.[18] The minimum sample size was 323 prescriptions per phase. All eligible physicians were included, and prescriptions were selected using systematic random sampling from the electronic prescribing database. In the preintervention phase, 5164 eligible prescriptions were available, and a sampling interval of 16 was applied to select 323 prescriptions; in the postintervention phase, 5539 eligible prescriptions were available, and a sampling interval of 17 was applied to select 323 prescriptions. In each phase, a random starting point was chosen, followed by sampling at constant intervals until the target sample size was reached.[19] A standardized data collection form was developed and pilot-tested. Physician characteristics (e.g., sex, age group, qualification, and years of practice) were obtained from the hospital administrative records. Patient and prescription data were extracted from the electronic system, including age, sex, comorbidities, ICD-10 diagnosis codes, number of medicines per prescription, and key dosing and administration instructions.[20] DRPs were identified through pharmacist review of all sampled prescriptions. Trained clinical pharmacists assessed each prescription using a hierarchical reference approach. Primary references included manufacturers’ product information, the Vietnam National Drug Formulary (2022),[21] Ministry of Health prescribing guidance, and the national list of contraindicated drug interactions (Decision No. 5948/QĐ-BYT).[14] When national or local sources were insufficient, international drug information resources were consulted as tertiary references (e.g., British National Formulary for Children [BNFC], AHFS Drug Information, Electronic Medicines Compendium, and Drugs.com). DRPs were first classified according to the national drug use review framework (Decision No. 3547/QĐ-BYT)[13] and subsequently mapped to the PCNE classification v9.1 to facilitate international comparability.[15] Operational definitions and decision rules for each DRP category are presented in Supplementary Table S1. Supplementary Table 1Drug-related problem categories and coding system based on Decision number: 3547/QĐ-BYT (Ministry of Health, Vietnam)Classification categoryCodeDrug selectionT1 Duplication of therapy (Lặp thuốc)T1.1 Drug interaction (Tương tác thuốc)T1.2 Wrong drug* (Sai thuốc)T1.3 Inappropriate route/dosage form (Đường dùng/dạng bào chế chưa phù hợp)T1.4 Contraindicated (Có chống chỉ định)T1.5 No indication (Không có chỉ định)T1.6 Too many drugs for the same indication (Quá nhiều thuốc cho cùng chỉ định)T1.7 Other drug selection problems (Vấn đề khác về lựa chọn thuốc)T1.99Dosage regimen/dosingT2 Dose too high (Liều dùng quá cao)T2.1 Dose too low (Liều dùng quá thấp)T2.2 Dosing frequency too high (Tần suất dùng quá nhiều)T2.3 Dosing frequency too low (Tần suất dùng không đủ)T2.4 Inappropriate timing (Thời điểm dùng chưa phù hợp)T2.5 Dose instructions inappropriate/unclear (Hướng dẫn liều chưa phù hợp, chưa rõ ràng)T2.6 Other dosing problems (Vấn đề khác về liều)T2.99Patient adherenceT3 Taking less than prescribed (Dùng thuốc không đủ liều như được kê đơn)T3.1 Taking more than prescribed (Dùng thuốc cao hơn liều như được kê đơn)T3.2 Irregular intake (Dùng thuốc không đều như được kê đơn)T3.3 Intentional misuse (Cố ý lạm dụng thuốc)T3.4 Dosage form difficult to use (Dạng bào chế khó sử dụng)T3.5 Other adherence problems (Vấn đề khác về tuân thủ)T3.99Insufficient treatment (Điều trị chưa đủ)T4 Untreated/insufficiently treated condition (Có bệnh lý chưa được điều trị đủ)T4.1 Need prophylaxis/insufficient prophylaxis (Cần biện pháp dự phòng/Chưa dự phòng đủ)T4.2 Other insufficient treatment problems (Vấn đề khác…)T4.99Treatment duration (Độ dài đợt điều trị)T5 Duration too short (Quá ngắn)T5.1 Duration too long (Quá dài)T5.2 Other duration problems (Vấn đề khác…)T5.99Requires monitoring (Cần được theo dõi)T6 Clinical manifestations (Biểu hiện lâm sàng)T6.1 Laboratory/paraclinical indicators (Các chỉ số cận lâm sàng)T6.2 Other monitoring problems (Vấn đề khác…)T6.99Toxicity and ADRs (Độc tính và ADR)T7 Patient experienced ADR (Bệnh nhân gặp ADR)T7.1 Drug toxicity/poisoning (Ngộ độc thuốc)T7.2Drug dispensing (Cấp phát thuốc)T8 Drug not available (Không sẵn có thuốc)T8.1 Strength not available (Không sẵn có hàm lượng)T8.2 Dosage form not available (Không sẵn có dạng bào chế)T8.3 Other dispensing problems (Vấn đề khác về cấp phát thuốc)T8.99Other unclassified problems (Vấn đề không được phân loại khác)T99*(as in Decision 3547): Wrong drug includes wrong active ingredient/drug name/strength (i.e., “sai tên hoạt chất/tên thuốc/nồng độ/hàm lượng”). ADRs=Adverse drug reactions Drug-related problem categories and coding system based on Decision number: 3547/QĐ-BYT (Ministry of Health, Vietnam) *(as in Decision 3547): Wrong drug includes wrong active ingredient/drug name/strength (i.e., “sai tên hoạt chất/tên thuốc/nồng độ/hàm lượng”). ADRs=Adverse drug reactions Based on findings from the preintervention assessment, a multifaceted pharmacist-led intervention was designed and implemented between February and March 2024. The intervention targeted outpatient pediatric prescribers who participated in the preintervention phase and was delivered by the principal investigator in collaboration with hospital clinical pharmacists. The intervention included two educational sessions (approximately 30 min each) that presented baseline DRP patterns, case-based examples derived from local prescriptions, and evidence-informed recommendations focusing on the most frequent DRP types (particularly dosing, timing/administration instructions, and key interaction precautions), followed by facilitated discussion. In addition, drug information bulletins summarizing key messages were disseminated (late February 2024). One reminder was delivered once (mid-March 2024) before the postintervention assessment, reiterating: (i) weight-/age-based dose calculation tips for the most frequently involved medicines; (ii) standardized administration-timing instructions for PPIs, antacids, corticosteroids, and Vitamin D; and (iii) common interaction precautions identified at baseline. The postintervention assessment was conducted from April 1 to May 31, 2024 using the same eligibility criteria, sampling strategy, data collection procedures, and DRP assessment methods as in the preintervention phase. The primary outcome was the proportion of prescriptions containing at least one DRP (≥1 DRP per prescription). Secondary outcomes included (i) the distribution of DRP categories and specific DRP subtypes, (ii) the intervention effectiveness index (relative reduction in DRP prevalence compared with baseline), and (iii) prescribing factors associated with DRP occurrence identified using logistic regression. Effectiveness was evaluated by comparing the primary and secondary outcomes between the pre and postintervention phases. Descriptive statistics were used to summarize physician, patient, and prescription characteristics. Differences in DRP prevalence and DRP-category proportions between phases were assessed using Chi-square tests. To examine prescribing factors associated with DRP occurrence, logistic regression was performed with the presence of ≥1 DRP per prescription as the dependent variable, and results were reported as odds ratios (ORs) with 95% confidence intervals (CIs). Statistical significance was set at P < 0.05. All analyses were performed using IBM SPSS Statistics (version 26.0; IBM Corp., Armonk, NY, USA). Ethical approval was obtained from an appropriately constituted institutional ethics committee prior to study initiation (approval number: 23.003.HV/PCT-HDDD). Administrative permission was granted by the study hospital. All extracted data were anonymized prior to analysis and handled confidentially. RESULTS A total of 24 prescribing physicians and 646 pediatric outpatient prescriptions were included in the analysis, comprising 323 prescriptions in the preintervention phase and 323 prescriptions in the postintervention phase. Among prescribing physicians, most were male (62.5%), younger than 40 years (79.2%), held postgraduate qualifications (58.3%), and had five or fewer years of clinical experience (66.7%). Baseline patient and prescription characteristics were comparable between the pre and postintervention phases, with no statistically significant differences observed for any variables (all P > 0.05). In both phases, the majority of patients were aged >2–6 years, and males accounted for slightly more than half of the sample. Most prescriptions contained 2 or fewer diagnoses and fewer than five medications, and approximately 3/4 of prescriptions were issued to patients with at least 1 comorbidity [Table 1]. Table 1Patient and prescription characteristics before and after interventionCharacteristicPreintervention, n (%)Postintervention, n (%) P Age groups (years) ≤269 (21.4)122 (37.8)0.331 >2–6200 (61.9)150 (46.4) >6–1242 (13.0)39 (12.1) >1212 (3.7)12 (3.7)Gender Male173 (53.6)177 (54.8)0.095 Female150 (46.4)146 (45.2)Diagnoses per prescription ≤2267 (82.7)246 (76.2)0.051 >256 (17.3)77 (23.8)Medications per prescription <5248 (76.8)267 (82.7)0.297 ≥575 (23.2)56 (17.3)Comorbidities Yes242 (74.9)240 (74.3)0.594 No81 (25.1)83 (25.7)P-values were calculated using Chi-square tests for categorical variables, P<0.05 indicates statistical significance Patient and prescription characteristics before and after intervention P-values were calculated using Chi-square tests for categorical variables, P<0.05 indicates statistical significance Before the intervention, 187 of 323 prescriptions (57.9%) contained at least one DRP. Of these, 133 prescriptions (41.2%) contained a single DRP, while 54 prescriptions (16.7%) contained two or more DRPs. A total of 243 DRPs were identified in the preintervention phase [Table 2 and Supplementary Table S2]. Dosage regimen-related problems (PCNE category T2) accounted for the vast majority of DRPs (97.12%). Incorrect timing of administration was the most frequent DRP (32.20%), followed by high dosage (29.72%) and low dosage (8.35%). Drug selection-related problems (PCNE category T1) were uncommon, representing only 2.88% of all identified DRPs. Table 2Prevalence and types of drug-related problems before interventionDRP categoryn (%)Prescriptions with DRPs ≥1 DRP187 (57.9) 1 DRP133 (41.2) ≥2 DRPs54 (16.7)Types of DRPs (total DRPs=243) Drug selection (T1)7 (2.88) Drug–drug interaction (T1.2)2 (0.62) Incorrect dosage form (T1.4)2 (0.62) Medication without indication (T1.6)3 (0.93)Dosage regimen (T2)236 (97.12) High dosage (T2.1)96 (29.72) Low dosage (T2.2)27 (8.35) Incorrect timing (T2.5)104 (32.20) Unclear dosage instruction (T2.6)9 (2.78)T1–T6 denote DRP categories from the national drug use review framework (Decision number: 3547/QĐ-BYT) mapped to PCNE v9.1, T1=Drug selection, T2=Dosage regimen/dosing, T3=Patient adherence, T4=Insufficient treatment, T5=Treatment duration, T6=Requires monitoring [Supplementary Table S1]. Percentages for DRP subtypes are calculated using the total number of identified DRPs as the denominator (total DRPs=243). DRPs=Drug-related problems, PCNE=Pharmaceutical Care Network Europe Prevalence and types of drug-related problems before intervention T1–T6 denote DRP categories from the national drug use review framework (Decision number: 3547/QĐ-BYT) mapped to PCNE v9.1, T1=Drug selection, T2=Dosage regimen/dosing, T3=Patient adherence, T4=Insufficient treatment, T5=Treatment duration, T6=Requires monitoring [Supplementary Table S1]. Percentages for DRP subtypes are calculated using the total number of identified DRPs as the denominator (total DRPs=243). DRPs=Drug-related problems, PCNE=Pharmaceutical Care Network Europe Supplementary Table 2Description of drug-related problems identified in pediatric outpatient prescriptions1. Drug selection-related DRPsNumberDRP descriptionSpecific cases identifiedRecommended information1Inappropriate indication of antihistamine (chlorpheniramine)Chlorpheniramine was prescribed for nonindicated conditionsIndications: Allergic conditions with pruritus1,5,6; common cold22Appropriate indications of probiotics/digestive enzymesB. clausii, L. acidophilus were prescribed appropriatelyB. clausii: Treatment/prevention of intestinal dysbiosis; restoration of gut microbiota after antibiotics; acute/chronic GI disorders1. L. acidophilus: Adjunctive treatment of diarrhea with oral rehydration; replenishment after antibiotic use1,23Esomeprazole was prescribed inconsistently with the diagnosisEsomeprazole was used without an appropriate indicationIndications: Peptic ulcer disease; NSAID-induced ulcers; Zollinger–Ellison syndrome1,2; GERD, erosive esophagitis, H. pylori infection3,5,64Cefuroxime tablets were prescribed at fractional doses250 mg or 500 mg tablets split/crushedCefuroxime tablets should not be split or crushed1,2,45Esomeprazole 40 mg tablets prescribed to children <12 yearsUse of adult-strength tablets in younger childrenEsomeprazole 40 mg tablets recommended for ≥12 years; children <12 years: 20 mg dose, avoid tablet formulation1,56Montelukast 5 mg tablets were prescribed to children <6 yearsUse in children aged 6–71 monthsRecommended dosing: 4 mg (6 months–5 years); 5 mg (6–14 years); 10 mg (≥15 years)1,3,5DRP=Drug-related problem, GI=Gastrointestinal, NSAID=Nonsteroidal anti-inflammatory drugs, GERD=Gastroesophageal reflux disease, L. acidophilus=Lactobacillus acidophilus, B. clausii: Bacillus clausii, H. pylori: Helicobacter pylori Description of drug-related problems identified in pediatric outpatient prescriptions 1. Drug selection-related DRPs DRP=Drug-related problem, GI=Gastrointestinal, NSAID=Nonsteroidal anti-inflammatory drugs, GERD=Gastroesophageal reflux disease, L. acidophilus=Lactobacillus acidophilus, B. clausii: Bacillus clausii, H. pylori: Helicobacter pylori Factors associated with the presence of at least one DRP per prescription are presented in Table 3. In multivariate logistic regression analysis, prescriptions issued by male physicians were significantly more likely to contain DRPs than those issued by female physicians (adjusted OR 2.513, 95% CI 1.511–4.180; P < 0.001). Compared with children aged ≤2 years, prescriptions for patients aged >2–6 years and >6–12 years were associated with significantly lower odds of DRP occurrence. Prescriptions containing five or more medications were also significantly associated with the presence of DRPs. Table 3Factors associated with drug-related problem occurrence (univariate and multivariate analyses)FactorsDRP, n (%)Non-DRP, n (%)Univariate OR (95% CI)Multivariate OR (95% CI) P Physician gender Male48 (44.0)61 (56.0)2.355 (1.471–3.772)2.513 (1.511–4.180)<0.001 Female (ref.)139 (65.0)75 (35.0)11Patient age groups (years) ≤2 (ref.)22 (32.4)46 (67.6)11 >2–6143 (67.1)70 (32.9)0.234 (0.131–0.419)0.226 (0.123–0.415)<0.001 >6–1218 (51.4)17 (48.6)0.452 (0.196–1.041)0.409 (0.173–0.968)0.042 ≥124 (57.9)3 (42.0)0.359 (0.074–1.743)0.457 (0.092–2.262)0.337Number of medications <5 (ref.)131 (52.8)117 (47.2)11<0.001 ≥556 (74.7)19 (25.3)2.632 (1.478–4.687)0.441 (0.282–0.688)Statistical significance was set at P<0.05. Univariate associations were assessed using logistic regression, multivariable logistic regression included variables with P<0.20 in univariate analysis. (ref.) indicates the reference category in regression analyses. OR=Odds ratio, CI=Confidence interval, DRPs=Drug-related problems Factors associated with drug-related problem occurrence (univariate and multivariate analyses) Statistical significance was set at P<0.05. Univariate associations were assessed using logistic regression, multivariable logistic regression included variables with P<0.20 in univariate analysis. (ref.) indicates the reference category in regression analyses. OR=Odds ratio, CI=Confidence interval, DRPs=Drug-related problems Following implementation of the pharmacist-led intervention, the proportion of prescriptions containing at least one DRP decreased significantly from 57.9% in the preintervention phase to 40.2% in the postintervention phase (P < 0.001) [Table 4]. Significant reductions were observed in several dosage regimen-related DRP categories, including high dosage, low dosage, incorrect timing of administration, and unclear dosage instructions. Although reductions were also observed in drug selection-related DRPs, these differences did not reach statistical significance. The overall intervention effectiveness index was 30.48%, indicating a substantial reduction in DRPs after implementation of the structured clinical pharmacy intervention. Table 4Drug-related problems frequency and categories before and after interventionDRP categoryPreintervention, n (%)Postintervention, n (%) P Overall DRP (≥1 DRP)187 (57.9)130 (40.2)<0.001Drug selection (T1) Drug–drug interaction (T1.2)2 (0.6)1 (0.3)0.318 Incorrect dosage form (T1.4)2 (0.6)1 (0.3)0.318 Medication without indication (T1.6)3 (0.92)1 (0.3)0.158Dosage regimen (T2) High dosage (T2.1)96 (29.72)65 (20.12)<0.001 Low dosage (T2.2)27 (8.35)18 (5.57)0.003 Incorrect timing (T2.5)104 (32.20)74 (22.91)<0.001 Unclear dosage instruction (T2.6)9 (2.78)5 (1.55)0.045P-values were calculated using Chi-square tests comparing pre versus postintervention proportions, statistically significant P values (P<0.05) are shown in the table. T1–T6 denote DRP categories from the national drug use review framework (Decision number: 3547/QĐ-BYT) mapped to PCNE v9.1 [Supplementary Table S1]. DRPs=Drug-related problems, PCNE=Pharmaceutical Care Network Europe Drug-related problems frequency and categories before and after intervention P-values were calculated using Chi-square tests comparing pre versus postintervention proportions, statistically significant P values (P<0.05) are shown in the table. T1–T6 denote DRP categories from the national drug use review framework (Decision number: 3547/QĐ-BYT) mapped to PCNE v9.1 [Supplementary Table S1]. DRPs=Drug-related problems, PCNE=Pharmaceutical Care Network Europe DISCUSSION This study provides a comprehensive evaluation of DRPs in pediatric outpatient prescriptions and demonstrates the effectiveness of a structured pharmacist-led intervention in a routine care setting in Vietnam. Prior to the intervention, more than half of outpatient prescriptions (57.9%) contained at least one DRP, indicating a substantial burden of potentially preventable medication-related problems in pediatric ambulatory practice. Following implementation of the intervention, DRP prevalence decreased significantly to 40.2%, corresponding to an absolute reduction of 17.7 percentage points and an intervention effectiveness index of 30.48%. Given the high volume of pediatric outpatient prescribing, this reduction is both statistically and clinically meaningful, as even modest improvements at the prescription level may translate into substantial cumulative reductions in medication-related risk. The magnitude of improvement observed in this study is consistent with previous Vietnamese and international evidence demonstrating that pharmacist involvement can improve prescribing quality and medication safety in pediatric settings.[1011] These findings are also aligned with the WHO’s Global Patient Safety Challenge “Medication Without Harm,” which emphasizes multidisciplinary and system-level strategies to reduce preventable medication-related harm, particularly in vulnerable populations such as children.[1] The preintervention prevalence of DRPs (57.9%) is comparable with that reported in earlier Vietnamese pediatric outpatient studies, which generally range from approximately 60% to 70%.[1118] International estimates of pediatric DRPs vary widely,[922] reflecting differences in study design, definitions, prescribing systems, and availability of age-appropriate formulations. This variability highlights the importance of generating local data to characterize context-specific prescribing problems and to inform targeted, feasible interventions. Dosage regimen-related problems overwhelmingly dominated the DRP profile in this study, accounting for more than 97% of identified DRPs before the intervention. This finding is consistent with the pediatric medication safety literature, which consistently identifies dosing and administration errors as the most frequent and preventable sources of harm in children.[4569] Factors such as weight-based dosing, dose calculations, formulation manipulation, and reliance on caregivers for administration increase vulnerability to these errors. In contrast, drug selection-related DRPs were relatively uncommon, which may partly reflect the influence of Vietnam’s prescribing regulations and structured drug use review frameworks, including Circular No. 18/2018/TT-BYT and Decisions No. 3547/QĐ-BYT and No. 5948/QĐ-BYT.[121314] The pharmacist-led intervention was associated with significant reductions in overall DRP prevalence and in most dosage regimen-related categories, findings that are consistent with evidence supporting pharmacist-led audit, feedback, and educational interventions in pediatric care.[31023] The largest improvements were observed in high-dose prescribing, incorrect timing of administration, and low-dose errors – DRP categories that were specifically targeted through baseline feedback, case-based discussions, and reinforced drug information bulletins. Reductions in drug selection-related DRPs did not reach statistical significance, likely due to their low baseline prevalence, suggesting that pharmacist-led interventions may have the greatest impact when focused on frequent and modifiable prescribing problems rather than rare errors. Multivariate analysis identified physician gender, patient age, and the number of medicines per prescription as factors associated with DRP occurrence. The observed association between male physicians and a higher likelihood of DRPs should be interpreted cautiously, as it may reflect unmeasured confounding factors such as differences in clinical roles, workload, or case complexity rather than gender-related differences in prescribing competence. The association between a higher number of prescribed medicines and increased DRP risk is consistent with existing evidence linking regimen complexity and polypharmacy to medication-related problems.[924] Age-related differences in DRP occurrence should also be interpreted carefully, given variations in dosing complexity, formulation availability, and prescribing practices across pediatric age groups.[922] This study has several strengths, including the use of systematic random sampling, application of nationally endorsed DRP classification frameworks mapped to PCNE version 9.1 to enhance international comparability, and evaluation of a pragmatic, low-cost intervention that can be integrated into routine practice. However, several limitations should be acknowledged. The single-center design limits generalizability, and the retrospective prescription review did not include patient follow-up or assessment of clinical outcomes. In addition, the absence of a concurrent control group limits causal inference. Although seasonal variation between study phases is possible, patient and prescription characteristics were comparable across phases, suggesting a limited impact on the observed findings. Future multicenter studies using interrupted time-series or cluster-based designs would strengthen causal inference and allow assessment of the sustainability of intervention effects. This study highlights the important role of clinical pharmacists in improving medication safety in pediatric outpatient care. Integrating structured pharmacist-led interventions – such as prescription audit and feedback, targeted education, and ongoing drug information support – represents a feasible and scalable strategy for reducing DRPs in similar hospital settings in Vietnam. This approach aligns with international medication safety priorities and national regulatory frameworks,[1121314] and supports broader investment in the development and integration of clinical pharmacy services within pediatric healthcare systems. CONCLUSIONS DRPs were frequent in pediatric outpatient prescriptions, with dosage regimen-related errors constituting the predominant and most preventable category. Implementation of a structured, pharmacist-led intervention within routine outpatient practice was associated with a substantial and clinically meaningful reduction in overall DRP prevalence. These findings highlight the important and often under-recognized contribution of clinical pharmacy services to improving prescribing quality and medication safety in pediatric care, particularly in low- and middle-income country settings. Integrating low-cost, scalable, pharmacist-led strategies – such as prescription audits, targeted education, and ongoing drug information support – offers a practical, feasible approach to reducing medication-related risks in resource-limited outpatient healthcare systems. AUTHOR CONTRIBUTIONS All authors contributed to the conception and design of the study. Lam Tran Hong Huynh coordinated the study, supervised data collection, and identified and classified DRPs. Thang Nguyen and Anh Ngoc Phuong Nguyen participated in data collection and data curation. Duy Khanh Dang conducted the statistical analyses and verified the results. Phuong Minh Nguyen contributed to the interpretation of the findings. Lam Tran Hong Huynh drafted the initial manuscript. Thang Nguyen, Anh Ngoc Phuong Nguyen, Duy Khanh Dang, and Phuong Minh Nguyen critically revised the manuscript for important intellectual content. All authors read and approved the final manuscript and agree to be accountable for all aspects of the work. Conflicts of interest There are no conflicts of interest. SUPPLEMENTARY TABLES 2. Dose-related DRPs 2.1. Dose too high NumberDRP descriptionSpecific cases identifiedRecommended dosing7Acetaminophen was prescribed above the recommended doseMultiple age groups receiving doses exceeding recommendationsAge-and weight-based dosing; repeat every 4–6 h if needed; maximum 4 doses/24 h1,2,58Acyclovir was prescribed above the recommended dose10-years-old (48 kg): 1.2 g/dose ×3/dayVaricella dosing: 200–800 mg ×4/day depending on age; adolescents: 800 mg ×5/day1-59Ambroxol was prescribed above the recommended dose7–22 months: 15 mg ×2/day<2 years: 7.5 mg ×2/day; 2–5 years: 7.5 mg ×3/day; use with caution in <5 years1-810Bromhexine was prescribed above the recommended doseExcess dosing across multiple age groups<10 years: 0.5 mg/kg/day in divided doses; age-specific regimens apply1,211Cefixime was prescribed above the recommended doseInfants and toddlers receiving excessive daily doses<12 years: 8 mg/kg/day (1–2 divided doses) or age-based fixed doses1-812Chlorpheniramine prescribed above the maximum doseChildren <6 and <12 years overdosedMaximum daily dose: <2 years: 2 mg; 2–6 years: 6 mg; 6–12 years: 12 mg; ≥12 years: 24 mg1-813Esomeprazole was prescribed above the recommended doseChildren 33 months–11 years: 40–80 mg/day1–11 years: 10–20 mg/day; 12–17 years: 20–40 mg/day1-5DRP=Drug-related problem DRP=Drug-related problem 2.2. Dose too low NumberDRP descriptionSpecific cases identifiedRecommended dosing14Acetylcysteine underdosing≥7 years: 200 mg ×2/day≥7 years: 200 mg ×3/day1,215Acyclovir underdosing44 months (15.5 kg): 400 mg ×3/day20 mg/kg×4/day or age-based dosing1-816Azithromycin underdosing for GI infections42 months (13 kg): 63 mg ×2/day10 mg/kg once daily; duration by indication3,6-8,1017Bromhexine underdosing64 months–11 years: 4 mg ×2/dayAge-appropriate regimens as above1,218Cefixime underdosing15–45 months: 50 mg/day<12 years: 8–10 mg/kg/day or age-based dosing1-8DRP=Drug-related problem, GI=Gastrointestinal DRP=Drug-related problem, GI=Gastrointestinal 3. DRPs related to the timing of administration NumberDRP descriptionSpecific cases identifiedRecommended administration19PPIs without meal-timing instructionsEsomeprazole/OmeprazoleTake ≥1 h before meals1,520Antacids without timing instructionsMagnesium hydroxide + aluminum hydroxideTake 1–3 h after meals and at bedtime; separate from other drugs1,2,5,a21Prednisolone without timing instructionsNo guidance providedTake with or after meals, preferably earlier in the day1,222Vitamin D2 without usage instructionsUndiluted administrationDilute in water, milk, or fruit juice before use1DRP=Drug-related problem, PPIs=Proton pump inhibitors DRP=Drug-related problem, PPIs=Proton pump inhibitors 4. Drug–drug interaction–related DRPs NumberDrug interactionClinical consequenceSeverityRecommended management23Prednisolone + IbuprofenIncreased risk of GI ulceration, bleedingModerateAvoid combination; if unavoidable, monitor GI symptoms and consider PPI prophylaxisa,b24Prednisolone + LactuloseElectrolyte imbalance, hypokalemiaModerateAvoid if possible; monitor electrolytes; limit laxative durationaPPI=Proton pump inhibitor, GI=Gastrointestinal PPI=Proton pump inhibitor, GI=Gastrointestinal Significance 1Package inserts 2Vietnam National Drug Formulary 2022 3AHFS Drug Information (www.drugs.com) 4Electronic Medicines Compendium (eMC) 5British National Formulary for Children (BNFC) 2019–2020 6Children’s Hospital No. 1 (2020). Pediatric treatment guidelines 7Children’s Hospital No. 1 (2016). Pediatric treatment guidelines 8 Ministry of Health (Vietnam) (2015). Pediatric diagnosis and treatment guidelines 9Official Letter No. 9234/QLD-DK (2015) 10 Ministry of Health (Vietnam). Decision No. 708/QĐ-BYT (2015) aDrug interaction database bClinical pharmacology references